Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.06
+9.9%
$0.07
$0.03
$0.11
$698K1.5218,078 shs1,936 shs
Functional Brands Inc. stock logo
MEHA
Functional Brands
$0.00
$0.04
$0.00
$8.00
$184KN/A22.24 million shs143,311 shs
Orgenesis Inc. stock logo
ORGS
Orgenesis
$0.00
+320.0%
$0.33
$0.00
$1.08
$22K3.141,073 shs1,010 shs
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
$0.01
-2.9%
$0.02
$0.01
$1.35
$594K1.55292,617 shs37,629 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
+9.91%+1.67%-23.75%+48.78%+62.67%
Functional Brands Inc. stock logo
MEHA
Functional Brands
0.00%-14.00%-31.75%-96.42%+429,900.00%
Orgenesis Inc. stock logo
ORGS
Orgenesis
+320.00%-98.87%-98.68%-97.38%-99.63%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-2.94%-18.01%-7.69%-21.89%-98.53%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
$0.06
+9.9%
$0.07
$0.03
$0.11
$698K1.5218,078 shs1,936 shs
Functional Brands Inc. stock logo
MEHA
Functional Brands
$0.00
$0.04
$0.00
$8.00
$184KN/A22.24 million shs143,311 shs
Orgenesis Inc. stock logo
ORGS
Orgenesis
$0.00
+320.0%
$0.33
$0.00
$1.08
$22K3.141,073 shs1,010 shs
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
$0.01
-2.9%
$0.02
$0.01
$1.35
$594K1.55292,617 shs37,629 shs
The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
+9.91%+1.67%-23.75%+48.78%+62.67%
Functional Brands Inc. stock logo
MEHA
Functional Brands
0.00%-14.00%-31.75%-96.42%+429,900.00%
Orgenesis Inc. stock logo
ORGS
Orgenesis
+320.00%-98.87%-98.68%-97.38%-99.63%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-2.94%-18.01%-7.69%-21.89%-98.53%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.00
N/AN/AN/A
Functional Brands Inc. stock logo
MEHA
Functional Brands
1.00
SellN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00
N/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MEHA, ORGS, WINT, and HEPA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/1/2026
Functional Brands Inc. stock logo
MEHA
Functional Brands
UpgradeSell (E-)Sell (E)
(Data available from 7/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/A$1.29 per shareN/A
Functional Brands Inc. stock logo
MEHA
Functional Brands
$6.67M0.03$0.02 per share0.27$0.09 per share0.05
Orgenesis Inc. stock logo
ORGS
Orgenesis
$662K0.03N/AN/A($6.58) per share0.00
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/A$0.98 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
-$48.93M-$72.15N/AN/AN/AN/A-812.56%-207.31%9/2/2026 (Estimated)
Functional Brands Inc. stock logo
MEHA
Functional Brands
$760K-$0.32N/AN/AN/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
-$55.36M-$11.51N/AN/AN/A-3,827.81%N/A-130.18%8/7/2026 (Estimated)
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$1.79M-$8.77N/AN/AN/AN/A-207.34%-50.19%8/19/2026 (Estimated)

Latest MEHA, ORGS, WINT, and HEPA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2026N/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
-$2.60N/AN/AN/A$2.80 millionN/A
5/15/2026Q1 2026
Functional Brands Inc. stock logo
MEHA
Functional Brands
N/A-$0.36N/A-$0.36N/A$1.65 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/AN/AN/AN/AN/A
Functional Brands Inc. stock logo
MEHA
Functional Brands
N/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
N/A
1.30
1.30
Functional Brands Inc. stock logo
MEHA
Functional Brands
0.25
1.20
0.64
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/A
0.07
0.07
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/A
0.43
0.25

Institutional Ownership

CompanyInstitutional Ownership
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
17.24%
Functional Brands Inc. stock logo
MEHA
Functional Brands
N/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
22.56%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
29.33%

Insider Ownership

CompanyInsider Ownership
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
0.06%
Functional Brands Inc. stock logo
MEHA
Functional Brands
4.26%
Orgenesis Inc. stock logo
ORGS
Orgenesis
1.91%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
0.15%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hepion Pharmaceuticals, Inc. stock logo
HEPA
Hepion Pharmaceuticals
2011.44 million6.63 millionNo Data
Functional Brands Inc. stock logo
MEHA
Functional Brands
3342.74 million40.92 millionN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
1505.17 million4.53 millionNo Data
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
3044.99 million3.66 millionNot Optionable

Recent News About These Companies

Windtree Therapeutics Delays Quarterly Report Filing

New MarketBeat Followers Over Time

Media Sentiment Over Time

Hepion Pharmaceuticals stock logo

Hepion Pharmaceuticals NASDAQ:HEPA

$0.06 +0.01 (+9.91%)
As of 07/17/2026 03:44 PM Eastern

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.

Functional Brands stock logo

Functional Brands NASDAQ:MEHA

$0.0043 0.00 (0.00%)
As of 07/17/2026 03:58 PM Eastern

Our company operates in the nutraceutical supplement industry. We are a manufacturer and distributor of supplements in categories such as pain, energy, prenatal, general health, bone and joint, gastro, immunity, cardiac, detox, mental clarity & focus, sleep, prenatal and urinary. Our end markets focus on end-consumers through different channels that include pharmacies, US wholesalers, international distributors and direct-to-consumers sales. Our products are sold over the counter, and consumers do not need a prescription to purchase our products. Our products are not approved by the FDA. Our company also operates in the hemp industry as a retailer of hemp derived products in categories such as capsules, cigarettes, gummies, and tinctures with a commercial end market, and end-consumers. Our Products Kirkman Brand Our “Kirkman” brand products are manufactured in our FDA registered, cGMP certified facility in Lake Oswego, Oregon. Established in 1949, Kirkman specializes in manufacturing nutritional supplements and is one of the oldest companies dedicated to serving the special needs community. Our Kirkman brand offers more than 150 products, including probiotics, enzymes, vitamins, multivitamins, amino acids, antioxidants, immune support, essential fatty acids, preconception, prenatal supplements, personal care products and other specialty products. Kirkman treats patients with autism spectrum disorders and special dietary needs through an established network of over 2,000 doctors in over 40 countries. Our Kirkman brand operates in 95% of the major subsegments in the supplement industry. Kirkman has a long-standing loyal customer and consumer base due to the rigorous testing of products in compliance with FDA requirements. Kirkman has been endorsed by various businesses and celebrities, including the famous and original Shark Tank member, Kevin Harrington. Digestive enzymes: Over the counter oral digestive enzyme supplements are a combination of proteases, which aid protein digestion; lipases, which aid in fat digestion; and amylases, which aid in carbohydrate digestion. These may be prescribed by a doctor in some cases, when the pancreas does not make enough digestive enzymes on its own. People are increasingly taking over the counter (“OTC”) digestive enzymes in lower doses to support general gut health. Essential fatty acids: Also called omega-3 fatty acids, essential fatty acids are important digestive chemicals that the body cannot make on its own. Our products under the Kirkman Brand include, but are not limited to, the following: . Supplements for Autism; . Essential Fatty Acids; . Oxytocin; . Vitamin B12; . Vitamin B6 and Magnesium; . Glutathione; . Melatonin; . Functional Mushrooms; . Probiotics; . Multivitamins and Minerals; and . Digestive Enzymes; . Antioxidants. . Amino Acids; P2i (prenatal) Brand We launched a certified prenatal vitamin in April 2024 for expectant mothers under the P2i by Kirkman brand. These vitamins have been specially formulated by our company to provide essential nutrients for both the mother and the developing fetus. The International Federation of Gynecology and Obstetrics (“FIGO”) published a position statement about toxic chemicals and environmental contaminants in prenatal vitamins. FIGO’s recommendation from the October 2023 position statement highlights that patients should only consume, and clinicians should only prescribe, vitamins and supplements that have been independently assessed to make certain they do not contain contaminants. Manufacturers should be held to a standard of production that assures safety and minimizes contaminants and certification of all prenatal vitamins becomes the standard of care. The FIGO Committee report on Climate Change and Toxic Environmental Exposures brought together global scientists to review reputable reference sources for chemicals that have the potential to impact maternal and newborn health, including the USA Environmental Protection Agency, the European Union, and the California EPA. The group of experts recommended several approaches, including: 1. creating a list of toxic chemicals and contaminants that should be screened for in Prenatal Vitamins and reduced to de minimis standards; and 2. conducting assays of existing vitamins to assess ongoing risk to maternal and newborn health. This work can extend to personal exposure risk by offering women testing for the presence of potentially toxic environmental chemicals. Mass Spectrometry currently offers the most comprehensive measurement. This first publication of a list of toxic chemicals and contaminants represents the most comprehensive testing available at present but does not purport to identify or eliminate all potential sources of toxicity. We are currently the only certified prenatal vitamin in the market that aligns to the FIGO position statement. We have formulated and produced a prenatal vitamin called P2i by Kirkman. There are approximately 3.6 million pregnancies alone in the United States (https://www.cdc.gov/nchs/fastats/births.htm) and the initial market focus for this product will be the United States with the expectation to expand globally since FIGO’s position statement reaches all countries. The P2i by Kirkman prenatal vitamin has been certified by The FORUM, a nonprofit 501(c)(3) organization dedicated to promoting low-toxicity standards for prenatal healthy products. The FORUM operates under a Memorandum of Understanding (MOU) with FIGO, a globally recognized organization of obstetricians and gynecologists. This MOU establishes a shared objective to reduce environmental toxicity in prenatal products. . The certification process involves rigorous testing and evaluation to ensure compliance with The FORUM’s low-toxicity standards, which align with FIGO’s objectives for maternal and fetal health. These standards include: . Analysis of 24 Heavy Metals, ensuring levels are below stringent safety thresholds . Testing for the presence of 120 toxic chemicals, such as pesticides and endocrine disruptors, with strict limits to prevent potential harm . Utilization of ISO 17025-accredited laboratories for all testing to ensure reliability and reproducibility of results . Purity Labs, an ISO 17025-accredited laboratory, as directed by The FORUM, conducted testing, which confirmed the product’s compliance with The FORUM’s criteria. Based on this testing, The FORUM issued its certification, indicating that Kirkman’s prenatal vitamin meets its standards for low toxicity and safety. HempTown Naturals Brand All HempTown Naturals products are produced and sold in compliance with the US 2018 Farm Bill and the US Agricultural Act of 2014. Cannabidiol (“CBD”) and cannabigerol (“CBG”) are cannabinoids present in the cannabis plant. Both CBD and CBG are used in hemp derived products. These products are believed to help in treating certain neurodegenerative and inflammatory conditions(1). CBD CBD is the second most prevalent ingredient in cannabis. While CBD is an integral component of medical marijuana, it is derived directly from the hemp plant, both of which are the same species of Cannabis sativa L. One of the hundreds of components of Cannabis sativa L., CBD does not cause a “high” by itself. According to a report from the World Health Organization, “In humans, CBD exhibits no effects indicative of any abuse or dependence potential. To date, there is no evidence of public health related products associated with the use of pure CBD”(2). As reported by Forbes Health, CBD is applied topically or consumed through smoke inhalation or edible consumption. CBD interacts with neuroreceptors in your endocannabinoid system, which sends signals between your cells to help regulate your movement, mood, homeostasis, and immune system. Different studies have shown that CBD can offset everyday anxiety and depression(3). CBG CBG is another compound found in hemp which doesn’t have intoxicatingly psychoactive effects. CBG, often referred to by experts as “the mother of all cannabinoids,” is the cannabinoid from which other types of cannabinoids (including CBD) are derived, says Michelle Sexton, a naturopathic doctor who works at the Pain Trauma Institute in San Diego. “CBG is the first compound in the biosynthesis (the production of chemical compounds by a living organism) of the other cannabinoids,” she adds. CBG is available in many forms, including tinctures, gummies, capsules and topical creams and lotions. CBG is often coupled with CBD in these products because the two cannabinoids can provide complimentary benefits, such as decreasing inflammation and pain, says Fraser Smith, a naturopathic doctor, as well as assistant dean and associate professor at the National University of Health Services in Lombard, Illinois. CBD and CBG occur naturally in hemp extract which is the source of our cannabinoids(4). Golf Mellow Brand The Company has utilized existing product formulations with plans to introduce 12 different products under the Golf Mellow brand. A brand logo and packaging has been created to support the existing formulations. These supplements will be targeting the golf industry and golf professionals. These products include capsules, a powder, a cream and tinctures to help golfers of all levels improve their game and overall well-being. The capsules are packed with a blend of essential vitamins and minerals that support joint health, flexibility, and energy levels. The tinctures are made from all-natural ingredients and provide a quick and easy way to support focus and mental clarity, helping athletes stay in the zone and make the perfect shot. The creams are specially designed to provide targeted relief for sore muscles and joints, helping them stay comfortable and focused on the course. Some of these products include Sleep Caps to ensure that players are well rested the night before, Super B12 Powder which provides the energy needed for the perfect round, Calm Caps which help manage anxiety when players need it most, and Epsom Salt Cream & Recovery Caps, which aids with recovery. According to data from the National Golf Foundation 28.1 million people (aged six and over) played on a golf course in the United States in 2024 – furthermore there were another 19.1 million people who took part in off-course activities like driving ranges, indoor golf simulators or venues like Topgolf(5). We are currently incorporated and in good standing in the State of Delaware. Our registered address is in Lake Oswego, Oregon.

Orgenesis stock logo

Orgenesis NASDAQ:ORGS

$0.0042 +0.00 (+320.00%)
As of 07/17/2026 09:58 AM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Windtree Therapeutics stock logo

Windtree Therapeutics NASDAQ:WINT

$0.01 0.00 (-2.94%)
As of 07/17/2026 03:52 PM Eastern

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.